Trauma segment experiences slight sequential gains as product intros gain traction and companies overcome supply disruption.

The WW Trauma Market ended Q2 posting +1.5% (reported) growth, with the US Market driving growth up 3.6% YOY, slightly up sequentially compared to Q1’s 3.2% gains. Internationally, Europe and ROW fared worse due to missed tenders, with -2.1% and -1.1% growth, respectively. Looking forward, SmartTRAK anticipates the trauma segment will see...

Among the many topics covered in the complete Q219 Trauma Market Recap* are:

Strategy and focus in Sports Medicine for H119

Looking back on the first half of 2019, SmartTRAK reported solid growth, +3.9% in the US and +3.2% WW, across the board in the Soft Tissue Fixation Market. After several years of acquisitions within the Sports Medicine Market, the major players are all able to boast about well-rounded portfolios and the ability to compete in a majority of the Sports Medicine subspecialties. Subspecialty focus, strategy and shifts in market share are now becoming the keys to success in this market. Industry meetings such as American Association of Orthopedic Surgeons (AAOS), Arthroscopy Association of North America (AANA) and American Orthopaedic Society for Sports Medicine (AOSSM) revealed...

Among the many topics covered in the H119 Soft Tissue Fixation Market Recap* are:

Sales strategy, market reach and evidence-based medicine drives strong Orthobiologics performance

SmartTRAK reports that Q219 performance in the OrthoBio market was strong, up 6% YoY, exceeding SmartTRAK expectations. As expected, Medtronic was the overall OrthoBio market leader, followed by DePuy Synthes and Stryker. Overall, all OrthoBio technologies grew year-over-year except for Spinal Constructs, Soft Tissue Augmentation and Synthetic Cartilage. Although the Spine market has stabilized, Spinal Constructs continues to slowly lose share due to...

Among the many topics covered in the Q219 OrthoBio Market Recap* are:

Tough YoY comps, delays and salesforce disruptions slows growth

The WW Market for Foot & Ankle Fixation was up +2.0%, as reported, during Q219, although down sequentially due to tough YoY comps. The US Foot & Ankle Fixation market also experienced a sequential decline in growth. The historically strong segment faced extremely tough YoY comparisons along with no new product launches to spur growth. H119 US growth of...

Among the many topics covered in the Q219 Extremities Market Recap* are:

Ahead of the Orthopedic Trauma Association (OTA) meeting, see what SmartTRAK’s Senior Analyst for Trauma & Extremities, Natasha Weeks, has to say about the latest trends in Trauma.

Natasha recently wrote a fascinating and informative article, "Trauma: Top Trends to Watch in 2019 and Beyond", in which she took a look back at 2018 and identified continuing and emerging trauma trends in the market that are likely to shape the landscape in 2019 and beyond. If you would like to download the article and discover SmartTRAK’s predictions for the top trauma market trends to watch, just click the button below.

Hips drive slight acceleration in TJR Market while Knees held steady

With two earnings seasons of 2019 behind us, US Total Joints Market growth of 1.7% for H119, as modeled by SmartTRAK Financial Dashboard, is trending below SmartTRAK projections of 2.6% growth for FY19. This trend is not surprising considering the heightened seasonality we’ve seen over the last few years in H2 due to high patient deductibles. US Total Joints Market growth strengthened slightly to 1.8% for Q219 compared to 1.6% in Q1 driven by...

Among the many topics covered in the Q219 Total Joints Market Recap* are:

Join SmartTRAK for breakfast and an Executive Panel on “Advanced Technologies: Shifts in the Spine Landscape” at McCormick Place in Chicago, IL on Sept 26th. A panel of experts will be on hand to discuss the latest in advanced technologies, interbody devices, materials and design, and the impact these changes pose from an FDA regulatory standpoint.

Date:              Thursday, September 26th, 2019
Time:              7:30am-8:30am
Location:      Hyatt Regency McCormick Place,  Chicago, IL
Room:            Jackson Park C&D

Panelists include:

Q219 saw marginal revenue growth amid single-injection momentum and competitive pricing pressure

The numbers are in and now that we are in the second quarter of 2019, the US Joint Fluid market seems to be getting off its slow-ish start of the year, gaining some momentum with the single-injection segment pushing the aggregate total revenue into positive growth, according to the recently published SmartTRAK Financial Dashboard. This, despite relentless and fierce pricing competition in the multi-injection arena. 

Among the many topics covered in the Q219 US Joint Fluid Market Recap* are:

SmartTRAK was once again cited as a trusted source for market data, this time in the Orthofix Q219 Earnings Call and press release.

Brad Mason, Orthofix's President and Chief Executive Officer, referenced the SmartTRAK Market Recap: OrthoBio Report in the press release and stated “Regarding the second quarter results, net sales were in line with our expectations, led by another quarter of outstanding performance in our Biologics products and notably, as reported by SmartTRAK ^®, Orthofix now has the number one market share position in the U.S. cellular allograft segment.”

SmartTRAK was cited once again as a trusted source for data in a press release from Smith & Nephew entitled "Smith & Nephew meniscal knee repair technology delivers 0% re-operation rate and 100% meniscal healing at six months shows first ever study of horizontal cleavage tears".